Guangdong Province’s Drug Exchange Center has completed the price disclosure process for medical consumables submitted by enterprises before April 1, 2025. Products not receiving objections during the publicity period have been officially published and incorporated into the negotiated procurement framework. This move underscores Guangdong’s commitment to enhancing price transparency and efficiency in medical supply procurement.

Policy Breakdown

• Price Confirmation: Enterprises confirmed pricing information through the provincial platform’s “New Negotiating Price Listing (Automatic Confirmation Project)” module.
• Public Disclosure: Products without objections during the publicity period are now available for negotiated procurement at or below listed prices.
• Follow-Up Actions: Products requiring information verification or with pending registration statuses will be listed after resolution.

Market Implications
The initiative is expected to streamline interactions between medical consumable suppliers and healthcare institutions, potentially accelerating market entry by 10–15%. Analysts at Guangdong Healthcare Market Research highlight improved price transparency as a key driver for reducing procurement costs.

Industry Impact
Medical consumable manufacturers are encouraged to align with Guangdong’s pricing and procurement frameworks to maintain market access. The policy emphasizes procedural integrity, reducing administrative burdens post-approval.

Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1911060639980195840